LARP6

Across TCGA pan-cancer cohorts, LARP6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LARP6 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LARP6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LARP6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where LARP6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.162	0.756	.001	24	view →
LSCC	OS	Tertile	II,III,IV	0.730	0.994	.008	23	view →
PDAC	OS	Quartile	III,IV	0.353	0.868	.015	18	view →
HNSC	DFS	Tertile	All	0.887	0.648	.025	6	view →
GBM	DFS	Quartile	All	0.892	0.613	.013	4	view →
LUAD	DFS	Median	II,III,IV	0.411	0.715	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LARP6–CCRCC (DFS)

Open the CCRCC breakdown →